MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 12, 2004; DOI: 10.1124/mol.104.000596


0026-895X/04/6605-1301-1309$20.00
Mol Pharmacol 66:1301-1309, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.000596v1
66/5/1301    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gould, K. A.
Right arrow Articles by Tilby, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gould, K. A.
Right arrow Articles by Tilby, M. J.

p53 Elevation in Relation to Levels and Cytotoxicity of Mono- and Bifunctional Melphalan-DNA Adducts

Katherine A. Gould, Cally Nixon, and Michael J. Tilby

Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, University of Newcastle, Newcastle upon Tyne, United Kingdom

We tested the hypothesis that bifunctional DNA adducts formed by a nitrogen mustard-based anticancer drug were more efficient than monofunctional adducts at causing elevation of p53, consistent with the difference in cytotoxicity. Human leukemia cell line ML-1 was exposed for 1 h to melphalan or its monofunctional derivative monohydroxymelphalan. Levels of DNA adducts, measured by specific immunoassay, were linearly related to the concentration of alkylating agent. Monohydroxymelphalan formed twice as many adducts as did equal concentrations of melphalan. After the removal of the alkylating agent, adduct levels were maintained or increased slightly up to 8 h and then decreased by 27 to 44% by 24 h. Alkaline elution analyses confirmed the absence of detectable DNA interstrand cross-links in cells exposed to monohydroxymelphalan. DNA single-strand breaks were detected after monohydroxymelphalan but not after melphalan. Levels of p53 were quantified by sensitive fluorogenic enzyme-linked immunosorbent assay at intervals up to 24 h after exposure of cells to various concentrations of melphalan and monohydroxymelphalan. The level of initially formed DNA adducts needed to cause elevation of p53 from a baseline level of 0.5 ng/mg total protein to 2 ng/mg was 5- to 8-fold higher for monohydroxymelphalan than melphalan. The concentrations of melphalan and monohydroxymelphalan (±S.D.) causing 50% growth inhibition were 1.2 ± 0.4 and 28.1 ± 1.6 µg/ml, respectively, a 23-fold difference. The adduct levels induced by these exposures were 9.3 and 420 nmol/g DNA for melphalan and monohydroxymelphalan, respectively, a 45-fold difference, which is considerably greater than the difference in efficacy at elevating p53.


Received May 12, 2004; accepted August 11, 2004

Address correspondence to: Dr. M. J. Tilby, Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, University of Newcastle, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom. E-mail: m.j.tilby{at}ncl.ac.uk




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. K. Augustine, Y. Yoshimoto, M. Gupta, P. A. Zipfel, M. A. Selim, P. Febbo, A. M. Pendergast, W. P. Peters, and D. S. Tyler
Targeting N-Cadherin Enhances Antitumor Activity of Cytotoxic Therapies in Melanoma Treatment
Cancer Res., May 15, 2008; 68(10): 3777 - 3784.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Muret, M. Yacoub, P. Terrier, F. Drusch, A. Laplanche, C. Gaudin, C. Richon, C. Le Pechoux, A. Le Cesne, F. J. Lejeune, et al.
p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-{alpha} and melphalan
Ann. Onc., April 1, 2008; 19(4): 793 - 800.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
P. H. Clingen, I. U. De Silva, P. J. McHugh, F. J Ghadessy, M. J. Tilby, D. E. Thurston, and J. A. Hartley
The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136
Nucleic Acids Res., June 8, 2005; 33(10): 3283 - 3291.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics